How will recent agency initiatives and likely future directions for regulatory CMC guidance impact the cellular immunotherapy space?

It has been a busy past year or two in terms of regulatory evolution and initiatives that impact cellular immunotherapy developers. David McCall, Senior Editor, BioInsights, invites Adeyemi Afuwape to unpack some key pieces of recent guidance on the regulatory CMC side, and to share his thoughts on what the future may hold in this regard.

Please enter your email to access content Read now